Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597710 | 0.87 | STAT3 (0.49) | NPC1RAB9AGAAMEN1KMT2A | |
| SCHEMBL5597515 | 0.83 | MAPT (0.53) | NPC1RAB9AGAAMEN1KMT2A | |
| SCHEMBL5597942 | 0.83 | TP53 (0.47) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL5597749 | 0.81 | NPC1 (0.46) | NPC1RAB9AGAAMAPTMAPK14 | |
| SCHEMBL5597685 | 0.79 | MAOA (0.44) | GAAMEN1KMT2AMAPTGRIK1 | |
| SCHEMBL5597514 | 0.79 | TRPV1 (0.44) | MEN1KMT2AMAPTGRIK1EPHX2 | |
| SCHEMBL5597625 | 0.78 | RAB9A (0.46) | NPC1RAB9AGAAMEN1KMT2A | |
| SCHEMBL5597595 | 0.77 | EPHX1 (0.46) | RAB9AKMT2AMAPTPOLBEPHX2 | |
| SCHEMBL5597734 | 0.77 | ALDH1A1 (0.41) | NPC1RAB9AGAAMEN1KMT2A | |
| SCHEMBL5597907 | 0.76 | DDX3X (0.57) | MEN1KMT2AMAPTMAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202734-B1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-05-02 | — | — | EP | claimed |
| EP-1202734-A4 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2004-09-01 | — | — | EP | claimed |
| JP-2003507328-A | — | — | 2003-02-25 | — | — | JP | claimed |
| US-6387900-B1 | ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-05-14 | — | — | US | claimed |
| EP-1202734-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | claimed |
| WO-2001012188-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-02-22 | — | — | WO | claimed |
| EP-1202734-B1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-05-02 | — | — | EP | disclosed |
| EP-1202734-A4 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2004-09-01 | — | — | EP | disclosed |
| US-6387900-B1 | ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-05-14 | — | — | US | disclosed |
| EP-1202734-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012188-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-02-22 | — | — | WO | disclosed |